Adriamycin combined with 10-day Ara-C, vincristine, and prednisone (10-day ADOAP) in the treatment of adult acute leukemia patients under fifty years of age. A Southwest Oncology Group Study

In a twelve-month period, 56 consecutive patients with acute leukemia, aged 15-50, were treated by administration of a 10-day continuous infusion of Ara-C in combination with adriamycin, oncovin and prednisone (10 day ADOAP). Of 50 evaluable patients, there were 39 complete remissions (78%) with a m...

Full description

Saved in:
Bibliographic Details
Published inAmerican journal of clinical oncology Vol. 5; no. 6; p. 641
Main Authors Schreiter, S L, Amare, M, Stuckey, W J, Oishi, N, Saiki, J H, Vial, R, Pendleton, O, Morrison, F S
Format Journal Article
LanguageEnglish
Published United States 01.12.1982
Subjects
Acute Disease
Adolescent
Adult
Antineoplastic Agents - administration & dosage
Bone Marrow - drug effects
Cytarabine - administration & dosage
Doxorubicin - administration & dosage
Drug Administration Schedule
Drug Evaluation
Drug Therapy, Combination
Female
Humans
Leukemia - drug therapy
Male
Middle Aged
Prednisone - administration & dosage
United States
Vincristine - administration & dosage
United States
Online AccessGet more information

Cover

More Information
Summary:In a twelve-month period, 56 consecutive patients with acute leukemia, aged 15-50, were treated by administration of a 10-day continuous infusion of Ara-C in combination with adriamycin, oncovin and prednisone (10 day ADOAP). Of 50 evaluable patients, there were 39 complete remissions (78%) with a median remission duration of 71 weeks. After adjustment for age and other known prognostic factors, the complete remission rate is still 10% higher than that found using a similar regimen without adriamycin.
ISSN:0277-3732
DOI:10.1097/00000421-198212000-00012